摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

10-nitro-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h][1,6]naphthyridin-6-one | 538366-76-6

中文名称
——
中文别名
——
英文名称
10-nitro-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h][1,6]naphthyridin-6-one
英文别名
10-Nitro-2,3-Methylenedioxy-5-[2-(N,N-Dimethylamino)Ethyl]-5H-Dibenzo[c,h] [1,6]Naphthyridin-6-One;21-[2-(dimethylamino)ethyl]-15-nitro-5,7-dioxa-11,21-diazapentacyclo[11.8.0.02,10.04,8.014,19]henicosa-1(13),2,4(8),9,11,14(19),15,17-octaen-20-one
10-nitro-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h][1,6]naphthyridin-6-one化学式
CAS
538366-76-6
化学式
C21H18N4O5
mdl
——
分子量
406.398
InChiKey
RNWGIKJBCNJMQN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    30
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    101
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    10-nitro-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h][1,6]naphthyridin-6-one 在 Ra-Ni 作用下, 以 乙醇 为溶剂, 反应 3.0h, 以74.4%的产率得到10-amino-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h][1,6]naphthyridin-6-one
    参考文献:
    名称:
    [EN] NITRO AND AMINO SUBSTITUTED TOPOISOMERASE AGENTS
    [FR] AGENTS DE LA TOPOISOMERASE SUBSTITUES PAR NITRO ET AMINO
    摘要:
    该发明提供了公式(I)的化合物:其中R1-R9、W和X具有规范中定义的任何含义,以及它们的药用盐。该发明还提供了包含公式(I)化合物的药物组合物,制备公式(I)化合物的方法,用于制备公式(I)化合物的有用中间体,以及使用公式(I)化合物治疗癌症的治疗方法。
    公开号:
    WO2004014918A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    Nitro and Amino Substitution in the D-Ring of 5-(2-Dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones:  Effect on Topoisomerase-I Targeting Activity and Cytotoxicity
    摘要:
    5H-8,9-Dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one exhibits potent TOP1-targeting activity and pronounced antitumor activity. It was hypothesized that replacement of the two methoxyl groups with a nitro substituent would allow for retention of similar activity. In this study 8-, 9-, and 10-nitro-5H-2,3-methylenedioxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h] [1,6]naphthyridin-6-one and their amino derivatives were synthesized and assessed for their relative TOP1-targeting activity and cytotoxicity. In the case of both the 8- and 9-nitro analogues, their TOP1-targeting activity and cytotoxicity are greater than that of camptothecin and comparable to that of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one.
    DOI:
    10.1021/jm020498a
点击查看最新优质反应信息

文献信息

  • [EN] NITRO AND AMINO SUBSTITUTED TOPOISOMERASE AGENTS<br/>[FR] AGENTS DE LA TOPOISOMERASE SUBSTITUES PAR NITRO ET AMINO
    申请人:UNIV RUTGERS
    公开号:WO2004014918A1
    公开(公告)日:2004-02-19
    The invention provides compounds of formula (I): wherein R1-R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula (I), and therapeutic methods for treating cancer using compounds of formula (I).
    该发明提供了公式(I)的化合物:其中R1-R9、W和X具有规范中定义的任何含义,以及它们的药用盐。该发明还提供了包含公式(I)化合物的药物组合物,制备公式(I)化合物的方法,用于制备公式(I)化合物的有用中间体,以及使用公式(I)化合物治疗癌症的治疗方法。
  • Nitro and amino substituted topoisomerase agents
    申请人:——
    公开号:US20040110760A1
    公开(公告)日:2004-06-10
    The invention provides compounds of formula I: 1 wherein R 1 -R 9 , W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.
    本发明提供公式I的化合物:1,其中R1-R9,W和X具有规范中定义的任何含义及其药学上可接受的盐。本发明还提供包括公式I化合物的药物组合物,制备公式I化合物的方法,用于制备公式I化合物的中间体以及使用公式I化合物治疗癌症的治疗方法。
  • US6989387B2
    申请人:——
    公开号:US6989387B2
    公开(公告)日:2006-01-24
  • Nitro and Amino Substitution in the D-Ring of 5-(2-Dimethylaminoethyl)- 2,3-methylenedioxy-5<i>H</i>-dibenzo[<i>c,h</i>][1,6]naphthyridin-6-ones:  Effect on Topoisomerase-I Targeting Activity and Cytotoxicity
    作者:Sudhir K. Singh、Alexander L. Ruchelman、Tsai-Kun Li、Angela Liu、Leroy F. Liu、Edmond J. LaVoie
    DOI:10.1021/jm020498a
    日期:2003.5.1
    5H-8,9-Dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one exhibits potent TOP1-targeting activity and pronounced antitumor activity. It was hypothesized that replacement of the two methoxyl groups with a nitro substituent would allow for retention of similar activity. In this study 8-, 9-, and 10-nitro-5H-2,3-methylenedioxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h] [1,6]naphthyridin-6-one and their amino derivatives were synthesized and assessed for their relative TOP1-targeting activity and cytotoxicity. In the case of both the 8- and 9-nitro analogues, their TOP1-targeting activity and cytotoxicity are greater than that of camptothecin and comparable to that of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one.
查看更多